HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hewitt, R. I. Articles by Anduze, R. Search for Related Content PubMed Articles by Hewitt, R. I. Articles by Anduze, R.

The First Year's Results of a Mass Treatment Program with Hetrazan for the Control of Bancroftian Filariasis on St. Croix, American Virgin Islands¹

The procedures and the results obtained 1 year after a mass therapy program with Hetrazan for the control of Bancroftian filariasis on St. Croix are described. The reduction in total microfilariaemia in 65 control patients treated with various doses of Hetrazen and re-examined 1 year later was from 96.5 to 99.6 per cent. Microfilaria-positives in the control group were reduced by 79.4 per cent. The average microfilarial count in 5 selected communities resurveyed 1 year after the treatment program was reduced 88.8 per cent, and the reduction of microfilaria-positives was 60 per cent. No disturbing systemic reactions occurred amongst the population during treatment. It is believed that these results demonstrate the practical value of mass therapy with Hetrazan for eliminating a large proportion of microfilariae within an endemic area for Bancroftian filariasis, and suggest the potentialities of this drug for the control of this disease.

¹ The drug for this project was furnished by the Lederle Laboratories Division, and the Calco Chemical Division, American Cyanamid Company.

² All from the Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York.

³ Formerly Chief Municipal Physician, St. Croix. Present address: Charlotte Amalie, St. Thomas, Virgin Islands, U. S. A.